Navigation Links
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
Date:7/22/2011

ctory to standard chemotherapy and for which there is presently no established therapy.

About TAS-102 Phase II clinical trial:

The Phase II trial was conducted with the participation of 172 patients at 20 medical institutions in Japan from August 2009 to April 2010. The target for the study is an area for which there is currently no fully established therapy -- specifically, patients refractory to standard chemotherapy for metastatic colorectal cancer who have received at least two or more regimens containing a fluoropyrimidine, irinotecan, and oxaliplatin. Patients were randomly assigned to the TAS-102 (114 cases) or a placebo (58 cases). The primary endpoint was overall survival. TAS-102 and placebo were administered at dose of 70mg/m2/day twice daily for five days followed by two days rest and repeated twice. This was followed by a 14-day rest period to make a 28-day schedule for one course. In both cohorts, the 28-day cycle was repeated until the established criteria for termination were met.

About Taiho Pharmaceutical:

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: "We strive to improve human health and contribute to the enrichment of society." In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing evidence-based medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit '/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator ... imaging centers in China , ... under which Concord Medical Services (International) Pte Ltd, ... to acquire the Fortis Surgical Hospital from Fortis ...
(Date:3/26/2015)... -- The Burzynski Research Institute, Inc. (BRI) announced today that ... Department of Surgery at Kurume University Medical Center ... published. The study, a randomized non-blinded phase 2 ... adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections ... A total of 65 patients, with histologically ...
(Date:3/26/2015)... Calif. , March 26, 2015 Huntington ... Gabriel Valley to perform transcatheter aortic valve replacement (TAVR), ... procedure is a revolutionary new way to replace an ... of a heart lung machine. The procedure ... team led by Azhil ( Alex) Durairaj , MD, ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... , EXTON, Pa., Nov. 23 ... LaunchTrends (TM): Feraheme report, the second ... AMAG,s new IV iron product, Feraheme, through the first six months ... information from 50 unique Nephrologists and qualitative information from a subset ...
... , FORT WORTH, Texas, Nov. 23 ... of specialty medical products, announced that it has filed it Q3 2009 ... the developments during the 2009 calendar year. , Q3 2009 sales ... , Shareholder equity as of the Q3 2009 increased to $3,327,892 ...
Cached Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 6
(Date:3/28/2015)... Purity Products®, a leading direct to ... of their revolutionary new weight loss product, MuffinStop™. ... placebo-controlled clinical studies to be effective in reducing ... is a combination of two traditionally used botanical ... to create one of the most innovative weight ...
(Date:3/28/2015)... LTW Cyber is an innovation hub ... the purpose of addressing the needs of the global ... own opportunities to grow while seeking collaborative opportunities with ... , Ventures in LTW Cyber focus on secure application ... identifying vulnerabilities and analyzing open source. As the ...
(Date:3/27/2015)... Island, NY (PRWEB) March 27, 2015 ... cancer-focused training and business criteria for the spa and ... services to clients who have experienced or are living ... the global Spafinder Wellness 365® Network, will be identified ... and recognized as a provider of safe, therapeutic services ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with ... provider for the 2015 and 2016 season. As the Storm’s ... an athletic trainer for the team throughout each season. Tonight, ... the Cleveland Gladiators at Amalie Arena; the game starts at ... us as it gives us the opportunity, to provide health ...
(Date:3/27/2015)... Texas (PRWEB) March 27, 2015 First ... 7am today. The new facility is located 12665 W Lake ... “As a resident of Summerwood, I look forward to delivering ... said Dr. Sowell, Facility Medical Director of First Choice Emergency ... Choice Emergency Room made a donation to Summer Creek High ...
Breaking Medicine News(10 mins):Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2
... patients, according to a recent study, are increasingly turning ... In this context physicians need to be aware of ... patients to the most reliable, accurate and updated information. ... Cancer Center in Philadelphia echoed these ideas at the ...
... Dr. Balakrishna Ganapat Rao Matapurkar, from Maulana Azad Medical ... winning the first patent on organ regeneration from the ... / repairing organs in human beings. ,A few ... patent on this technique. Dr. Matapurkar was able ...
... has come out with a damning disclosure that half the ... Tobacco Day 2001," World Health Organization chief Gro Harlem Brundtland ... because most governments still allowed smoking in public places. She ... no safe permissible levels of second hand smoke. ,"Far ...
... Pfizer on the Indian front has run into rough ... subsidiary Parke-Davis (India). A local court in Hyderabad ... the city. ,The vacation court of the Ranga ... and machinery of Parke-Davis (India) following a petition filed ...
... forward by Brazil, at the annual assembly of the ... breast-feeding for the first six months in all infants. ... on Wednesday after 2 hours of debate where many ... for breast-feeding. ,Nestle, a maker of infant formula ...
... reproductive scientists plan to launch a human cloning clinic, ... 18 months, according to a US infertility specialist, Dr. ... Univeristy of Kentucky, is not medically qualified but holds ... and director of two USD infertility clinics, the Kentucky ...
Cached Medicine News:Health News:Scientists plan human cloning clinic in the United States 2
... automated 100-position ESR analyzer designed for laboratories ... instrument accurately and precisely measures the sedimentation ... ESR-Vacuum Tubes. Results are measured in millimeters ... available in 30 minutes. The ESR-100 features ...
... Sysmex CA-1500 enhances productivity in the laboratory ... three detection methods clotting, chromogenic and ... and precise test results every time. ... options and random access, the CA-1500 will ...
... Qwik-Let Elite has become one of ... This popularity is due to the ... in the design and function of ... device is priced for far less ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
Medicine Products: